Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of “Moderate Buy” from Analysts

Vor Biopharma Inc. (NASDAQ:VOR) has earned an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $42.25.

VOR has been the subject of a number of recent research reports. Wells Fargo & Company initiated coverage on Vor Biopharma in a research report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price for the company. Wedbush boosted their target price on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. HC Wainwright restated a “buy” rating and issued a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. Finally, Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. sold 165,150 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total value of $2,604,415.50. Following the completion of the sale, the director owned 2,402,095 shares in the company, valued at $37,881,038.15. The trade was a 6.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 3,002,903 shares of company stock valued at $49,412,176. Insiders own 0.45% of the company’s stock.

Institutional Trading of Vor Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Fcpm Iii Services B.V. bought a new stake in Vor Biopharma in the third quarter valued at approximately $18,496,000. UBS Group AG lifted its position in Vor Biopharma by 284.8% in the fourth quarter. UBS Group AG now owns 292,118 shares of the company’s stock valued at $3,821,000 after purchasing an additional 216,209 shares during the last quarter. Chung Wu Investment Group LLC bought a new stake in Vor Biopharma in the fourth quarter valued at approximately $109,000. China Universal Asset Management Co. Ltd. bought a new stake in Vor Biopharma in the fourth quarter valued at approximately $36,000. Finally, Sei Investments Co. bought a new stake in Vor Biopharma in the first quarter valued at approximately $245,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Stock Performance

NASDAQ:VOR opened at $14.33 on Tuesday. The business has a 50 day moving average of $15.06 and a 200 day moving average of $13.73. Vor Biopharma has a 1-year low of $3.30 and a 1-year high of $65.80.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. Equities analysts predict that Vor Biopharma will post -2.51 EPS for the current year.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).